Managing DAPT around π₯ surgery post-stent placement is all about balancing π©Έ bleeding vs. 𧱠thrombosis risk. Letβs break down the essentials:
β‘οΈ ACC guidelines: Recommend β±οΈ 6-12 mos of DAPT after most stents, but shorter durations are possible if π©Έ risk is high. π Chest guidelines note thrombosis risk is highest within 3 mos post-stent, though data are limited.
π Key points for peri-op DAPT decisions:
- Stents > 3 mos ago: π Hold P2Y12 inhibitors pre-op. Guidelines suggest:
- Brilique (ticagrelor) π 3-5 days; Plavix (clopidogrel) π 5 days; Effient (prasugrel) β³ 7 days
- β Avoid IV antiplatelet bridging (e.g., Integrilin, Aggrastat, Kengreal) due to limited data and π©Έ risk.
- βοΈ Exceptions may apply for recent MI, multiple stents, or critical artery stents where specialists may suggest bridging.
- Stents β€ 3 mos ago: If π©Έ risk is low, DAPT might continue pre-op. If high, hold the P2Y12 inhibitor. Consider IV antiplatelet bridging with high thrombotic risk and consult specialists.
- Bridging tips: π‘ No one IV antiplatelet is superior, but Kengreal (cangrelor) has a short half-life and no renal dosing. π° Costs can be high. Start IV antiplatelets within 72 hrs after stopping oral P2Y12 inhibitors, continue until ~1-6 hrs pre-op, then restart DAPT within 24 hrs post-op.
- π Discharge: Document the intended DAPT duration.
References
- Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2022;162(5):e207-e243.
- Chen AT, Patel M, Douketis JD. Perioperative management of antithrombotic therapy: a case-based narrative review. Intern Emerg Med. 2022;17(1):25-35.
- Van Tuyl JS, Newsome AS, Hollis IB. Perioperative Bridging With Glycoprotein IIb/IIIa Inhibitors Versus Cangrelor: Balancing Efficacy and Safety. Ann Pharmacother. 2019;53(7):726-737.